Accelerate Regenerative Wound Healing
ElectroFiber 3DTM Wound Matrix is a bioengineered, electrospun synthetic polymer matrix used as a resorbable synthetic graft for the management of partial to full thickness wounds.
Unleash the Potential of Synthetics to Accelerate Regenerative Wound Healing
ElectroFiber 3D™ Supports low pH and accelerates regenerative wound healing:
- Bioengineered, resorbable synthetic polymer technology
- Comprised of PGA and PLCL
- Synthetic polymers demonstrates a reduction in pH from 7.4 to 5.9 within 78 hours; to 4 within 2 weeks 9
- Agonistic to microbes 3-8
- Accelerates the wound healing process 1,2,10
- <8 weeks to wound closure 2,10
- Demonstrates a reduction wound associated pain scores after 1st application 1,10
- 2 or fewer applications, on average to closure 2,10
- 510K cleared for the management of partial to full thickness acute and chronic wounds, and burns
Chronic Surgical Wound
Time to Heal
65 days 2
Chronic DFU
Time to Heal
42 days 2
Chronic PI
Time to Heal
77 days 2
VLU
Time to Heal
30 days 2
WHAT IS ELECTROFIBER 3DTM WOUND MATRIX?
ElectroFiber 3DTM Wound Matrix is a bioengineered, electrospun synthetic polymer matrix used as a resorbable synthetic graft for the management of partial to full thickness wounds.
IS ELECTROFIBER 3DTM WOUND MATRIX CLEARED AS A 510K MEDICAL DEVICE?
Yes, ElectroFiber 3DTM Wound Matrix is cleared as a 510K medical device.
HOW DOES ELECTROFIBER 3DTM WOUND MATRIX DIFFER FROM CTPS?
ElectroFiber 3DTM Wound Matrix is bioengineered utilizing two resorbable synthetic polymers—polyglycolic acid (PGA) and poly lactide co-caprolactone (PLCL). Through a patented manufacturing process, ElectroFiber 3DTM Wound Matrix provides a non-woven, microporous scaffold that acts as a stimulus for cellular migration, infiltration and proliferation. Via hydrolysis, ElectroFiber 3DTM Wound Matrix naturally resorbs contributing glycolic, lactic and caproic acids to the wound microenvironment to correct, restore and accelerate the body’s natural wound healing process.
WHAT IMPACT DOES ELECTROFIBER 3DTM WOUND MATRIX HAVE ON PH?
During in vitro degradation testing in isotonic PBS solution, the matrix demonstrated a drop in pH from 7.4 to 4.75 over one week.17
HOW IS ELECTROFIBER 3DTM WOUND MATRIX APPLIED?
ElectroFiber 3DTM Wound Matrix should be applied within the confines of the wound following appropriate debridement. ElectroFiber 3DTM Wound Matrix may be affixed using steri-strips or surgical glue as needed and covered with a nonadherent dressing.
WHAT IS THE TOTAL TIME FOR DEGRADATION OF ELECTROFIBER 3DTM WOUND MATRIX?
The total time for degradation is between 7 – 14 days. ElectroFiber 3DTM Wound Matrix may be applied weekly or biweekly at the provider’s discretion.
Ordering Information
| Part # | Size | CM 2 |
|---|---|---|
| EF3D-1020 | 10 x 20 cm | 200 |
| EF3D-1010 | 10 x 10 cm | 100 |
| EF3D-0505 | 5 x 5 cm | 25 |
1. Dickson, L., Gerecht, S., Engineered Biopolymeric Scaffolds for Chronic Wound Healing, Front. Physiol., 2016, Sec. Clinical and Translational Physiology, https://doi.org/10.3389/fphys.2016.00341;
2. Kaufman T, Eichenlaub EH, Angel MF, Levin M, Futrell JW (1985) Topical acidification promotes healing of experimental deep partial thickness skin burns: a randomised double-blind preliminary study. Burns 12: 84–90.;
3. Leveen H, Falk G, Borek B, Diaz C, Lynfield Y, Wynkoop B, Mabunda GA et al (1973) Chemical acidification of wounds. An adjuvant to healing and the unfavourable action of alkalinity and ammonia. Ann Surgery 178(6): 745–50.;
4. Jones, E.M., C.A. Cochrane, and S.L. Percival, The Effect of pH on the Extracellular Matrix and Biofilms. Adv Wound Care (New Rochelle), 2015. 4(7): p. 431-439.;
5. Schneider, L.A., et al., Influence of pH on wound-healing: a new perspective for wound-therapy? Arch Dermatol Res, 2007. 298(9): p. 413-20.;
6. Gethin, G., The significance of surface pH in chronic wounds. Wounds UK, 2007 .;
7. B, G., et al., Proteases and pH in chronic wounds. Journal of Wound Care, 2005. 14(2): p. 59-61.;
8. Das A, Sinha M, Datta S, Abas M, Chaffee S, Sen CK, Roy S. Monocyte and macrophage plasticity in tissue repair and regeneration. Am J Pathol. 2015 Oct;185(10):2596-606. doi: 10.1016/j.ajpath.2015.06.001. Epub 2015 Jun 26. PMID: 26118749; PMCID: PMC4607753.;
9. Haller HL, Sander F, Popp D, Rapp M, Hartmann B, Demircan M, Nischwitz SP, Kamolz LP. Oxygen, pH, Lactate, and Metabolism-How Old Knowledge and New Insights Might Be Combined for New Wound Treatment. Medicina (Kaunas). 2021 Nov 1;57(11):1190. doi: 10.3390/medicina57111190. PMID: 34833408; PMCID: PMC8617754.;
10. Kroner, E.; Kaiser, J.S.; Fischer, S.C.; Arzt, E. Bioinspired polymeric surface patterns for medical applications. J. Appl. Biomater. Funct. Mater. 2012, 10, 287–292.;
11. Zieker D, Schäfer R, Glatzle J, Nieselt K, Coerper S, Kluba T, Northoff H, Königsrainer A, Hunt TK, Beckert S. Lactate modulates gene expression in human mesenchymal stem cells. Langenbecks Arch Surg. 2008 May;393(3):297-301. doi: 10.1007/s00423-008-0286-6. Epub 2008 Feb 14. Erratum in: Langenbecks Arch Surg. 2009 Mar;394(2):405. Kluba, Torsten [added]. PMID: 18273635.;
12. Schneider CC, Ateschrang A, Königsrainer I, Glatzle J, Bühler S, Schaefer R, Northoff H, Königsrainer A, Zieker D. Lactate influences the gene expression profile of human mesenchymal stem cells (hMSC) in a dose dependant manner. Cell Physiol Biochem. 2012;30(6):1547-56. doi: 10.1159/000343342. Epub 2012 Dec 10. PMID: 23234875.;
13. Lim, H. W., S.A.B Collins, J.S. Resneck, Jr, et al. 2017. The burden of skin disease in the United States. J. Am. Acad. Dermatol. 76: 958-972.e2.;
14. Driver, V.R., R.J. Snyder, T. Conner-Kerr & T. Thomas. 2014. AAWC Fact Sheet 1: CHRONIC WOUNDS The most important health problem you’ve never heard about. AAWC. Accessed January 24, 2018.;
15. Caroline E. Fife, Kristen A. Eckert, and Marissa J. Carter. Publicly Reported Wound Healing Rates: The Fantasy and the Reality. Advances in Wound Care. Mar 2018.77- 94.http://doi.org/10.1089/wound.2017.0743;
16. Lambert, C. Jake, Aviles, F., et al., The efficacy of a novel 3-D electrospun synthetic polymer matrix (3DESPM) for the management of difficult-to-heal wounds, Symposium on Advanced Wound Care poster presentation, 5.2022;
17. Horn CP, Fierro AL, Lantis JC 2nd. The Shift to Synthetics: A Review of Novel Synthetic Matrices for Wound Closure. Surg Technol Int. 2023 Sep 15;42:75-86. PMID: 37802070.
Explore our Entire Product Line
Autologous Advanced Biologics
Advanced Synthetics
About Royal
Royal is a pioneering leader in orthobiologic and wound care research and development. Royal’s commitment lies in delivering top-tier, innovative biologic solutions that enhance the healing process and improve patients' quality of life. Royal places patient well-being at the center of its mission, offering exceptional solutions to address a variety of complex needs.
At Royal, our mission is driven by patient-centered care, innovation and excellence, and integrity and compassion. Royal provides a comprehensive array of products tailored to meet the varied needs of the orthobiologic and wound care industry.
As a rapidly expanding force in the industry, Royal is continuously developing and launching new products and solutions that set benchmarks for quality, effectiveness, and patient outcomes. Royal’s commitment to research and innovation keeps it at the forefront of the industry, helping to shape the future of healthcare and improving lives.